Literature DB >> 9806061

Asymptomatic sexually transmitted disease prevalence in four military populations: application of DNA amplification assays for Chlamydia and gonorrhea screening.

S K Brodine1, M A Shafer, R A Shaffer, C B Boyer, S D Putnam, F S Wignall, R J Thomas, B Bales, J Schachter.   

Abstract

The prevalence of asymptomatic chlamydial and gonococcal infections in male and female military populations was determined using urine-based ligase chain reaction DNA amplification assays (DAAs). Cross-sectional surveys in four military settings revealed an overall prevalence of asymptomatic chlamydial infection of 4.2% (56/1338). This included 3.4% (21/618) of Western Pacific shipboard US Marine Corps enlisted men; 5.2% (21/406) of male marines shore-based in Okinawa, Japan; 2.7% (5/183) of female enlisted US Navy subtender personnel in dry dock; and 6.9% (9/131) of shore-based female naval personnel in San Diego. No gonococcal infections were detected. All subjects were treated within 2 weeks of screening; none of them had progressed to symptomatic disease. General population-based screening for asymptomatic sexually transmitted diseases, and in particular chlamydial infection, can be successfully implemented using urine-based DAA tests. Benefits are maximized in a population in which compliance for follow-up therapy is high.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806061     DOI: 10.1086/515685

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Incidence of recurrent diagnoses of Chlamydia trachomatis genital infections among male and female soldiers of the US Army.

Authors:  S D Barnett; J F Brundage
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

2.  Evaluation of dry and wet transported intravaginal swabs in detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in female soldiers by PCR.

Authors:  Charlotte A Gaydos; Kimberly A Crotchfelt; Nina Shah; Marie Tennant; Thomas C Quinn; Joel C Gaydos; Kelly T McKee; Anne M Rompalo
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Screening sexually active adolescents for Chlamydia trachomatis: what about the boys?

Authors:  Kathleen P Tebb; Robert H Pantell; Charles J Wibbelsman; John M Neuhaus; Ann C Tipton; Samantha C Pecson; Meaghan Pai-Dhungat; Timothy H Ko; Mary-Ann B Shafer
Journal:  Am J Public Health       Date:  2005-10       Impact factor: 9.308

4.  High-risk behavior and sexually transmitted infections among U.S. active duty servicewomen and veterans.

Authors:  Vinita Goyal; Kristin M Mattocks; Anne G Sadler
Journal:  J Womens Health (Larchmt)       Date:  2012-09-20       Impact factor: 2.681

5.  Circumcision and the risk of prostate cancer.

Authors:  Jonathan L Wright; Daniel W Lin; Janet L Stanford
Journal:  Cancer       Date:  2012-03-12       Impact factor: 6.860

6.  The Use of Urine and Self-obtained Vaginal Swabs for the Diagnosis of Sexually Transmitted Diseases.

Authors:  Charlotte A. Gaydos; Anne M. Rompalo
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

7.  Prevalence and factors associated with asymptomatic gonococcal and chlamydial infection among US Navy and Marine Corps men infected with the HIV: a cohort study.

Authors:  Robert J Carpenter; Oliver N Refugio; Nehkonti Adams; Kevin P O'Brien; Mark D Johnson; Harold L Groff; Ryan C Maves; Mary F Bavaro; Nancy F Crum-Cianflone
Journal:  BMJ Open       Date:  2013-05-28       Impact factor: 2.692

8.  Comparison of Abbott LCx Chlamydia trachomatis assay with Gen-Probe PACE2 and culture.

Authors:  D C Young; S Craft; M C Day; B Davis; E Hartwell; S Tong
Journal:  Infect Dis Obstet Gynecol       Date:  2000

9.  The Association between Sexually Transmitted Infections, Length of Service and Other Demographic Factors in the U.S. Military.

Authors:  Robert Deiss; Richard J Bower; Edgie Co; Octavio Mesner; Jose L Sanchez; Jennifer Masel; Anuradha Ganesan; Grace E Macalino; Brian K Agan
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.